EC Investigating Lundbeck Regarding Generic Drug Entry

The EC is investigating Danish pharmaceutical company Lundbeck to determine whether it took improper actions intended to hinder the entry of generic citalopram, and anti-depressant drug, into European markets. 

This entry was posted on January 11, 2010 at 1:08 pm, filed under EU News, Patent Litigation, Section 2 Standards. Bookmark the permalink. Follow any comments here with the RSS feed for this post. Post a comment or leave a trackback: Trackback URL.

One Comment